These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

292 related items for PubMed ID: 22096922

  • 41. A chronic subdural hematoma in a patient receiving combination therapy with pegylated interferon alfa-2b and ribavirin for chronic hepatitis C.
    Goto T, Ohshima S, Miura K, Shibuya T, Sato W, Dohmen T, Kamada K, Kanata R, Sakai T, Chiba M, Sugimoto Y, Minami S, Ohnishi H.
    Intern Med; 2013; 52(18):2057-60. PubMed ID: 24042512
    [Abstract] [Full Text] [Related]

  • 42. Treatment of hepatitis C virus infection in patients on maintenance hemodialysis: a single United Arab Emirates center experience.
    Giguere A, Anas A, Nasser T, Hassan MH, Ahmed U, Beejay N, Nouh M, Khalowf M, Saleh A, Khan A, Attia M, El-Azab G.
    Eur J Intern Med; 2011 Dec; 22(6):582-6. PubMed ID: 22075284
    [Abstract] [Full Text] [Related]

  • 43. [Thyroid dysfunctions in children with chronic hepatitis C during interferon alpha-2b therapy].
    Kupś-Rzepecka J, Woźniakowska-Gesicka T, Gołabek V.
    Przegl Lek; 2011 Dec; 68(6):311-5. PubMed ID: 22039668
    [Abstract] [Full Text] [Related]

  • 44. [Hepatitis C therapy is not pleasant. Patients must be prepared!].
    MMW Fortschr Med; 2003 Jan 23; 145(3-4):57. PubMed ID: 12619237
    [No Abstract] [Full Text] [Related]

  • 45. [Information for patients. Treatment of acute hepatitis C].
    Otón Nieto E.
    Rev Esp Enferm Dig; 2011 Oct 23; 103(10):549. PubMed ID: 22054273
    [No Abstract] [Full Text] [Related]

  • 46. [Pegylated interferon plus ribavirin in chronic hepatitis C. More than half of patients show a lasting response].
    Zeuzem S.
    MMW Fortschr Med; 2002 Feb 21; 144(8):30-4. PubMed ID: 11910820
    [Abstract] [Full Text] [Related]

  • 47. Randomized trial of peginterferon alpha-2b plus low and escalating dose of ribavirin in patients with chronic hepatitis C with high viral load genotype 1.
    Iwasaki Y, Araki Y, Taniguchi H, Okamoto R, Kobashi H, Ikeda F, Miyake Y, Takaki A, Yamamoto K.
    J Med Virol; 2015 Apr 21; 87(4):625-33. PubMed ID: 25611729
    [Abstract] [Full Text] [Related]

  • 48. Pegylated interferon-α2a plus ribavirin for chronic hepatitis C in a real-life setting: the Hepatys French cohort (2003-2007).
    Bourlière M, Ouzan D, Rosenheim M, Doffoël M, Marcellin P, Pawlotsky JM, Salomon L, Fagnani F, Rouanet S, Pinta A, Vray M.
    Antivir Ther; 2012 Apr 21; 17(1):101-10. PubMed ID: 22267474
    [Abstract] [Full Text] [Related]

  • 49. Extended duration therapy with pegylated interferon and ribavirin for patients with genotype 3 hepatitis C and advanced fibrosis: final results from the STEPS trial.
    Shoeb D, Dearden J, Weatherall A, Bargery C, Moreea S, Alam S, White E, Vila X, Freshwater D, Ryder S, Mills PR, Alexander GJ, Forton D, Foster GR.
    J Hepatol; 2014 Apr 21; 60(4):699-705. PubMed ID: 24291239
    [Abstract] [Full Text] [Related]

  • 50. Efficacy and safety of peginterferon α-2a (40 KD) plus ribavirin in treatment-naive chronic hepatitis C patients in Central and Eastern Europe.
    Urbanek P, Oltman M, Ivanovski L, Rehák V, Messinger D, Tietz A, Husa P.
    Eur J Gastroenterol Hepatol; 2011 Nov 21; 23(11):1004-10. PubMed ID: 21904204
    [Abstract] [Full Text] [Related]

  • 51. Tongue hyperpigmentation during hepatitis C treatment.
    Bachmeyer C, Pellen JC.
    CMAJ; 2012 Sep 18; 184(13):1498. PubMed ID: 22451683
    [No Abstract] [Full Text] [Related]

  • 52. "Hepatitis C (HCV) treatment is not a "one size fits all".
    Bukeirat FA, Bukeirat MM.
    W V Med J; 2012 Sep 18; 108(2):20, 22-4. PubMed ID: 22655431
    [Abstract] [Full Text] [Related]

  • 53. Decline in pulmonary function during chronic hepatitis C virus therapy with modified interferon alfa and ribavirin.
    Foster GR, Zeuzem S, Pianko S, Sarin SK, Piratvisuth T, Shah S, Andreone P, Sood A, Chuang WL, Lee CM, George J, Gould M, Flisiak R, Jacobson IM, Komolmit P, Thongsawat S, Tanwandee T, Rasenack J, Sola R, Messina I, Yin Y, Cammarata S, Feutren G, Brown KK.
    J Viral Hepat; 2013 Apr 18; 20(4):e115-23. PubMed ID: 23490379
    [Abstract] [Full Text] [Related]

  • 54. Interstitial pneumonitis after treatment for hepatitis C virus infection.
    Botnaru V, Munteanu O, Rusu D.
    Pneumologia; 2015 Apr 18; 64(1):46-50. PubMed ID: 26016056
    [Abstract] [Full Text] [Related]

  • 55. Treatment of chronic hepatitis C in patients with glucose-6-phosphate dehydrogenase deficiency: is ribavirin harmful?
    Balestrieri C, Serra G, Cauli C, Chessa L, Balestrieri A, Farci P.
    Blood; 2006 Apr 15; 107(8):3409-10. PubMed ID: 16597599
    [No Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57. Pure red-cell aplasia associated with pegylated interferon-alpha-2b plus ribavirin.
    Miura Y, Kami M, Yotsuya R, Toda N, Komatsu T.
    Am J Hematol; 2008 Sep 15; 83(9):758-9. PubMed ID: 18615552
    [No Abstract] [Full Text] [Related]

  • 58. Very short course of triple therapy including telaprevir for chronic hepatitis C: a possible strategy in selected patients.
    Corti G, Salomoni E, Baragli F.
    Int J Infect Dis; 2014 Feb 15; 19():85-6. PubMed ID: 24246771
    [Abstract] [Full Text] [Related]

  • 59. Comparison of the efficacy of ribavirin plus peginterferon alfa-2b for chronic hepatitis C infection in patients with and without coagulation disorders.
    Honda T, Katano Y, Kuzuya T, Hayashi K, Ishigami M, Itoh A, Hirooka Y, Nakano I, Ishikawa T, Toyoda H, Kumada T, Yamamoto K, Matsushita T, Kojima T, Takamatsu J, Goto H.
    J Med Virol; 2013 Feb 15; 85(2):228-34. PubMed ID: 23160930
    [Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.